A Rare

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed, 27 citations in OpenAlex.

1. Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis.Molecular cancer research : MCR · 2026
   Article
2. Clinical and surveillance outcomes of the TP53 c.1000G > C (p.Gly334Arg) variant.Familial cancer · 2026
   Article
3. Low-penetrance TP53 variants are mainly hypomorphic: an underestimated issue with high clinical significance.NPJ genomic medicine · 2026
   Article
4. A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.Genome medicine · 2025
   Review
5. TP53 p.R181H is enriched in the Swedish cohort (SWEP53) and associated with a distinct breast and prostate phenotype.Scientific reports · 2025
   Article
6. Transmission ratio distortion of germline TP53 variants in Li-Fraumeni syndrome families.Cancer · 2025
   Article
7. Clinical and genetic characteristics of carriers of the TP53 c.541C > T, p.Arg181Cys pathogenic variant causing hereditary cancer in patients of Arab-Muslim descent.Familial cancer · 2024
   Article
8. The Ashkenazi-Centric G334R Variant ofMolecular and cellular biology · 2024
   Article
9. Association ofmedRxiv : the preprint server for health sciences · 2023
   Article
10. Emerging insights into ethnic-specific TP53 germline variants.Journal of the National Cancer Institute · 2023
    Review
11. An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression.Cancer discovery · 2023
    Article
12. TP53 mutations in Romanian patients with colorectal cancer.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2023
    Article
13. Common activities and predictive gene signature identified for genetic hypomorphs ofProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
14. Li-Fraumeni Syndrome: Mutation ofCancers · 2022
    Review
15. TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.Briefings in bioinformatics · 2022
    Article
16. Inherited TP53 Variants and Risk of Prostate Cancer.European urology · 2022
    Article
17. Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants.Molecular cancer research : MCR · 2022
    Article
18. Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain significance in BRCA1, TP53, and PTEN.American journal of human genetics · 2021
    Article
19. WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells.Cancers · 2021
    Article
20. Rare deleterious germline variants and risk of lung cancer.NPJ precision oncology · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

36 authors at 12 institutions in 1 country.

Funding

Abstract

Indexed as